Phagocidal Macrophages: A New Battle Tactic Against Resistant Cancers

Cancer immunotherapies are saving lives, but researchers still have a long journey ahead of them. Many cancers that are initially sensitive to immunotherapy acquire resistance over time, while others are resistant from the beginning.

In this episode, Niki Spahich from The Scientist’s Creative Services Team spoke with Stephanie Dougan, an associate professor of immunology at Harvard Medical School and a principal investigator at Dana Farber Cancer Institute, about her research developing new immunotherapies for resistant tumors.

LabTalk is a special edition podcast produced by The Scientist's Creative Services Team, where we explore topics at the leading edge of innovative research. This month’s episode is sponsored by 10x Genomics.


Stephanie Dougan, PhD
Associate Professor, Immunology
Harvard Medical School
Principle Investigator
Dana Farber Cancer Institute



This episode is brought to you by 10x Genomics, which builds solutions for interrogating biological systems at a resolution and scale that matches the complexity of biology. Their rapidly expanding suite of products, which includes instruments, consumables, and software, enables fundamental discoveries across multiple research areas, including cancer, immunology, and neuroscience.

Listen Now

TS_Podcast_LabTalk_10x Genomics_Phagocidal Macrophages: A New Battle Tactic Against Resistant Cancers

Information you provide will be held in confidence and will be shared with the sponsoring vendor(s) of this podcast. We may use the information to contact you about your account and to let you know about related programs and products; you may opt-out at any time. This allows The Scientist to keep these podcasts free of charge for our readers.